沙美特罗对COPD患者SaO2及肺功能的影响研究(1)
摘 要：目的 观察吸入沙美特罗对慢性阻塞性肺疾病患者睡眠期动脉血氧饱和度和睡眠质量的影响。方法 选择我院2015年1月～12月慢性阻塞性肺疾病患者60例，随机分为沙美特罗组和对照组，各30例。沙美特罗组接受吸入沙美特罗治疗，对照组接受安慰剂治疗。比较两组患者的SaO2、睡眠质量指数和肺功能指标。结果 治疗后，沙美特罗组睡眠期SaO2为(93.03±7.43)%，对照组为(91.21±9.01)%，差异有统计学意义(P<0.05)；且沙美特罗组睡眠期TST90为(2.40±0.4)%，对照组TST90为(19.53±1.72)%，差异有统计学意义(P<0.05)。治疗后，沙美特罗组患者肺功能较对照组改善，沙美特罗组FRC为(5.70±0.49)L，对照组为(6.23±0.54)L，差异有统计学意义(P<0.05)；两组睡眠质量指数比较，差异无统计学意义(P>0.05)。结论 吸入沙美特罗可改善COPD患者睡眠期SaO2，对睡眠质量无显著影响。
关键词：慢性阻塞性肺疾病；沙美特罗；动脉氧饱和度；睡眠质量
, http://www.100md.com
中图分类号：R563.9 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.20.013
文章编号：1006-1959(2018)20-0042-04
Abstract：Objective To observe the effect of inhaled salmeterol on arterial oxygen saturation and sleep quality in patients with chronic obstructive pulmonary disease during sleep.Methods 60 patients with chronic obstructive pulmonary disease from January to December 2015 in our hospital were randomly divided into salmeterol group and control group，30 cases each.The salmeterol group received inhaled salmeterol and the control group received placebo.SaO2，sleep quality index and lung function index were compared between the two groups.Results After treatment，the SaO2 in the salmeterol group was(93.03±7.43)%，the control group was(91.21±9.01)%，the difference was statistically significant(P<0.05)；and the salmeterol group sleep period TST90 was(2.40±0.4)%，the control group TST90 was(19.53±1.72)%，the difference was statistically significant(P<0.05).After treatment，the lung function of the salmeterol group was improved compared with the control group，the FRC of the salmeterol group was(5.70±0.49)L，and the control group was (6.23±0.54)L，the difference was statistically significant(P<0.05)；There was no significant difference in sleep quality index between the two groups(P>0.05).Conclusion Inhaled salmeterol can improve the sleep stage SaO2 in patients with COPD，and has no significant effect on sleep quality.
, 百拇医药
Key words：Chronic obstructive pulmonary disease；Salmeterol；Arterial oxygen saturation；Sleep quality
慢性阻塞性肺疾病(chronic obstructive pulmonary disease，COPD)是呼吸科最为常见的导致老年人生活质量下降和死亡的疾病，其特点为进展性的不完全可逆性的气流受限，气道重塑和肺功能下降[1-3]。由于睡眠时体位的影响，呼吸相关肌肉肌力下降、功能残气量下降等，导致睡眠时通气量不足，因此睡眠期低氧血症在COPD患者中非常常见[4，5]。低氧血症不但影响患者睡眠质量，还会加重COPD患者病情，可导致肺动脉高压、心律失常，甚至猝死等严重后果。氧疗和药物治疗是纠正睡眠期低氧血症的有效方法。长效β2受体激动剂(long-actingβ2 agonists，LABA)，作为治疗中重度COPD的药物，可增加第一秒用力呼气量(forced expiratory volume in 1 s，FEV1)，减少肺过度充气，从而减缓COPD患者病情的恶化[6]。本临床试验研究了LABA类药物沙美特罗吸入剂对睡眠期动脉血氧饱和度(SaO2)和睡眠质量的影响，现汇报如下。
1 资料与方法
1.1 一般资料 选择2015年1月～12月于昆明医科大学第二附属医院就诊的稳定期COPD患者60例，纳入标准：①年龄>50岁；②FEV1/用力肺活量(FVC)≤70%以及FEV1≤65%預计值；③觉醒期动脉氧分压(PaO2)≤75 mmHg。排除标准为：①冠心病、高血压、心率失常、惊厥、甲状腺毒症等；②近期接受氧疗；③存在COPD并发症；④睡眠呼吸暂停综合征(睡眠暂停或减弱≥10 次/h)；⑤合并哮喘；⑥1个月内存在呼吸道感染病史；⑦应用吸入糖皮质激素>1500 μg/d或口服糖皮质激素>10mg/d。, http://www.100md.com(陈晶 杜娟 牛学琴)
关键词：慢性阻塞性肺疾病；沙美特罗；动脉氧饱和度；睡眠质量
, http://www.100md.com
中图分类号：R563.9 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.20.013
文章编号：1006-1959(2018)20-0042-04
Abstract：Objective To observe the effect of inhaled salmeterol on arterial oxygen saturation and sleep quality in patients with chronic obstructive pulmonary disease during sleep.Methods 60 patients with chronic obstructive pulmonary disease from January to December 2015 in our hospital were randomly divided into salmeterol group and control group，30 cases each.The salmeterol group received inhaled salmeterol and the control group received placebo.SaO2，sleep quality index and lung function index were compared between the two groups.Results After treatment，the SaO2 in the salmeterol group was(93.03±7.43)%，the control group was(91.21±9.01)%，the difference was statistically significant(P<0.05)；and the salmeterol group sleep period TST90 was(2.40±0.4)%，the control group TST90 was(19.53±1.72)%，the difference was statistically significant(P<0.05).After treatment，the lung function of the salmeterol group was improved compared with the control group，the FRC of the salmeterol group was(5.70±0.49)L，and the control group was (6.23±0.54)L，the difference was statistically significant(P<0.05)；There was no significant difference in sleep quality index between the two groups(P>0.05).Conclusion Inhaled salmeterol can improve the sleep stage SaO2 in patients with COPD，and has no significant effect on sleep quality.
, 百拇医药
Key words：Chronic obstructive pulmonary disease；Salmeterol；Arterial oxygen saturation；Sleep quality
慢性阻塞性肺疾病(chronic obstructive pulmonary disease，COPD)是呼吸科最为常见的导致老年人生活质量下降和死亡的疾病，其特点为进展性的不完全可逆性的气流受限，气道重塑和肺功能下降[1-3]。由于睡眠时体位的影响，呼吸相关肌肉肌力下降、功能残气量下降等，导致睡眠时通气量不足，因此睡眠期低氧血症在COPD患者中非常常见[4，5]。低氧血症不但影响患者睡眠质量，还会加重COPD患者病情，可导致肺动脉高压、心律失常，甚至猝死等严重后果。氧疗和药物治疗是纠正睡眠期低氧血症的有效方法。长效β2受体激动剂(long-actingβ2 agonists，LABA)，作为治疗中重度COPD的药物，可增加第一秒用力呼气量(forced expiratory volume in 1 s，FEV1)，减少肺过度充气，从而减缓COPD患者病情的恶化[6]。本临床试验研究了LABA类药物沙美特罗吸入剂对睡眠期动脉血氧饱和度(SaO2)和睡眠质量的影响，现汇报如下。
1 资料与方法
1.1 一般资料 选择2015年1月～12月于昆明医科大学第二附属医院就诊的稳定期COPD患者60例，纳入标准：①年龄>50岁；②FEV1/用力肺活量(FVC)≤70%以及FEV1≤65%預计值；③觉醒期动脉氧分压(PaO2)≤75 mmHg。排除标准为：①冠心病、高血压、心率失常、惊厥、甲状腺毒症等；②近期接受氧疗；③存在COPD并发症；④睡眠呼吸暂停综合征(睡眠暂停或减弱≥10 次/h)；⑤合并哮喘；⑥1个月内存在呼吸道感染病史；⑦应用吸入糖皮质激素>1500 μg/d或口服糖皮质激素>10mg/d。, http://www.100md.com(陈晶 杜娟 牛学琴)